Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injection for subcutaneous use. It treats rheumatoid arthritis, psoriasis, Crohn's disease and certain leukemias, and is administered under specialist supervision.

GNH USA supplies Metoject as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is a disease-modifying antirheumatic drug (DMARD) that modulates immune and inflammatory pathways.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and reduces plaque formation. - Crohn's disease: decreases intestinal inflammation and promotes remission. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes. - Transient rash.

Serious or Rare Side Effects: - Bone marrow suppression leading to severe cytopenias. - Hepatotoxicity with potential fibrosis or cirrhosis. - Pulmonary fibrosis or interstitial pneumonitis. - Renal toxicity with impaired clearance. - Severe infections due to immunosuppression. - Anaphylactic or hypersensitivity reactions.

Before initiating Metoject, clinicians should evaluate organ function and patient risk factors.

- Renal function: assess baseline creatinine and monitor because the drug is renally excreted. - Liver function: perform regular transaminase tests to detect hepatotoxicity. - Hematology: obtain complete blood counts before and during therapy to watch for cytopenias. - Pregnancy: avoid use; methotrexate is teratogenic and contraindicated in pregnancy. - Infection risk: screen for latent infections and ensure appropriate vaccinations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medications that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: potentiate bone marrow suppression. - Live vaccines: risk of severe infection.

Moderate Interactions (Monitor Closely): - Penicillins: may reduce clearance, monitor renal function. - Proton pump inhibitors: can affect absorption, observe for renal changes. - Alcohol: can exacerbate hepatotoxicity; advise limitation.